SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials

SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

  • Market Cap: ₹2,465Cr.
  • Current Price: ₹55.9
  • Stock P/E: 68.4
  • ROE: 28.9%
  • ROCE: 36.9%
  • Book Value: ₹2.05
  • Dividend Yield: 0.02%
  • 52W High / Low: ₹65.3/26.3

In Jun 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹24 Cr and net profit ₹15 Cr.

Annual TTM: sales ₹75 Cr, net profit ₹36 Cr.

Shareholding: Promoters 51.16% (Aug 2026), DIIs 0.11% (Aug 2026), Public 48.74% (Aug 2026), No. of Shareholders 28,384% (Aug 2026).

SHUKRAPHAR quarterly results (₹ Cr.)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales611135639624
Expenses576461262
Operating Profit1471-027121
OPM %12%37%55%24%-7%69%11%90%
Other Income11112111
Interest00000000
Depreciation11111111
Profit before tax1481027020
Tax %39%23%29%26%-1,090%24%568%26%
Net Profit1351220-215
EPS in Rs0.010.070.120.020.050.46-0.040.34
Raw PDF————————
SHUKRAPHAR profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1211205975335775
Expenses1010185355202826
Operating Profit213519132949
OPM %13%13%14%9%26%39%51%65%
Other Income00013454
Interest00000111
Depreciation11222334
Profit before tax001420132948
Tax %82%-90%26%1%7%28%23%—
Net Profit001419102236
EPS in Rs0.000.000.020.100.420.220.500.81
Dividend Payout %0%0%10%4%6%5%2%—
SHUKRAPHAR balance sheet (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22224114444
Reserves1414141521471946
Borrowings681035345
Other Liabilities710101545172023
Total Liabilities28343635757887117
Fixed Assets1617181820201922
CWIP222222212
Investments00000000
Other Assets1114161653566584
Total Assets28343635757887117
SHUKRAPHAR cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity01183-583
Cash from Investing Activity-2-3-2-2-4-1-1-14
Cash from Financing Activity222-7512-55
Net Cash Flow0-00-0462-6
Free Cash Flow-2-2-16-1-75-13
CFO/OP25%81%38%292%64%-24%92%17%
SHUKRAPHAR shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Aug 2026
Promoters50.95%50.95%50.95%50.95%50.95%50.95%50.95%51.16%
DIIs0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%
Public48.93%48.93%48.93%48.93%48.93%48.92%48.93%48.74%
No. of Shareholders17,84418,23120,33721,44125,64927,17328,38428,384
SHUKRAPHAR key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days34524531813218712098148
Inventory Days1001692211392519447320
Days Payable1,16178670230327159414232
Cash Conversion Cycle-717-372-163-32-5880131236
Working Capital Days4402262785741157404352
ROCE %4%0%1%6%19%44%22%37%
SHUKRAPHARUpdated 26 Sept 2026, 20:55

Shukra Pharmaceuticals L

Market Cap

₹2,465Cr.

Current Price

₹55.9

High / Low

₹65.3/26.3

Stock P/E

68.4

ROE28.9%
ROCE36.9%
Book Value₹2.05
Face Value₹1.00
Dividend Yield0.02%

About

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Aug 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days737117520034524531813218712098148
Inventory Days55492112531001692211392519447320
Days Payable2911084007341,16178670230327159414232
Cash Conversion Cycle33554-112-480-717-372-163-32-5880131236
Working Capital Days7582583443794402262785741157404352
ROCE %-1%6%7%6%4%0%1%6%19%44%22%37%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

The reported market capitalisation for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is ₹2,465Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SHUKRAPHAR?

The current price shown for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux is ₹55.9 with a 52-week high/low of ₹65.3/26.3.

What is the P/E ratio of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

The stock P/E for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is 68.4 on Fincrux, with ROE at 28.9% and ROCE at 36.9%.

What were SHUKRAPHAR latest quarterly results?

For Jun 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹24 Cr and net profit ₹15 Cr (figures in ₹ crore unless noted).

What are SHUKRAPHAR annual sales and net profit?

For TTM, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) shows sales of ₹75 Cr and net profit of ₹36 Cr on the Fincrux profit & loss statement.

Who owns SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

Latest shareholding for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux: Promoters 51.16% (Aug 2026), DIIs 0.11% (Aug 2026), Public 48.74% (Aug 2026), No. of Shareholders 28,384% (Aug 2026).

Where can I find SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials?

SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SHUKRAPHAR balance sheet and cash flow?

Yes. The SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 26 September 2026 at 20:55


Designed & Shipped by Harshit Bansal